Journal of Antimicrobial Chemotherapy (2000) 45, 295-303
© 2000 The British Society for Antimicrobial Chemotherapy
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998)
a Medical Microbiology Division, 251 MRC, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA; b Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo, Brazil
The potency and spectrum of various antimicrobial agents tested against 434 bacterial isolates causing urinary tract infection (UTI) in hospitalized patients in Latin America were evaluated. The genotypes of the extended-spectrum ß-lactamase-producing and selected multi-resistant isolates were also evaluated by molecular typing techniques. Escherichia coli (60.4%) was the most common aetiological agent causing UTI, followed by Klebsiella spp. (11.2%) and Pseudomonas aeruginosa (8.3%). In contrast, Enterococcus spp. isolates caused only 2.3% of UTIs. Fewer than 50% of E. coli isolates were susceptible to broad-spectrum penicillins. The resistance rates to ciprofloxacin and the new quinolones were also high among these isolates. The molecular characterization of ciprofloxacin-resistant E. coli showed that most of them have a double mutation in the gyrA gene associated with a single mutation in the parC gene. The Klebsiella pneumoniae isolates studied demonstrated high resistance rates to ß-lactam drugs, including broad-spectrum cephalosporins. The carbapenems were the compounds with the highest susceptibility rate among these isolates (100.0% susceptible) followed by cefepime (91.7% susceptible). Meropenem, imipenem and cefepime were also the most active drugs against Enterobacter spp. Among P. aeruginosa isolates, meropenem (MIC50, 2 mg/L) was the most active compound, followed by imipenem (MIC50, 4 mg/L), cefepime (MIC50, 8 mg/L) and ceftazidime (MIC50, 16 mg/L). The results presented in this report confirm that bacterial resistance continues to be a great problem in Latin American medical institutions.
* Corresponding author. Tel: +1-319-335-8186; Fax: +1-319-335-8141; E-mail: galesa{at}mail.medicine.uiowa.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Ferrieres, V. Hancock, and P. Klemm Biofilm exclusion of uropathogenic bacteria by selected asymptomatic bacteriuria Escherichia coli strains Microbiology, June 1, 2007; 153(6): 1711 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Chenia, B. Pillay, and D. Pillay Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens J. Antimicrob. Chemother., December 1, 2006; 58(6): 1274 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uzunovic-Kamberovic Antibiotic resistance of coliform organisms from community-acquired urinary tract infections in Zenica-Doboj Canton, Bosnia and Herzegovina J. Antimicrob. Chemother., August 1, 2006; 58(2): 344 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Johnson, B. Johnston, M. A. Kuskowski, R. Colodner, and R. Raz Spontaneous Conversion to Quinolone and Fluoroquinolone Resistance among Wild-Type Escherichia coli Isolates in Relation to Phylogenetic Background and Virulence Genotype Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4739 - 4744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Johnson, A. C. Murray, A. Gajewski, M. Sullivan, P. Snippes, M. A. Kuskowski, and K. E. Smith Isolation and Molecular Characterization of Nalidixic Acid-Resistant Extraintestinal Pathogenic Escherichia coli from Retail Chicken Products Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2161 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Feria, E. Ferreira, J. D. Correia, J. Goncalves, and M. Canica Patterns and mechanisms of resistance to {beta}-lactams and {beta}-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal J. Antimicrob. Chemother., January 1, 2002; 49(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hryniewicz, K. Szczypa, A. Sulikowska, K. Jankowski, K. Betlejewska, and W. Hryniewicz Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland J. Antimicrob. Chemother., June 1, 2001; 47(6): 773 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Sahm, C. Thornsberry, D. C. Mayfield, M. E. Jones, and J. A. Karlowsky Multidrug-Resistant Urinary Tract Isolates of Escherichia coli: Prevalence and Patient Demographics in the United States in 2000 Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1402 - 1406. [Abstract] [Full Text]
|
|